Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as to create a talented workforce for the Fourth Industrial Revolution
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
This approval is a significant achievement in expanding the availability of this critical therapeutic,
Subscribe To Our Newsletter & Stay Updated